The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations

Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations

July 6, 2021 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Patients’ concerns may be well founded, according to recent data. Dr. Paik is one of the co-authors of a new study of 123 patients with rheumatic diseases who were tested for COVID-19 antibodies at baseline and prior to their second mRNA vaccine dose between Jan. 8 and Feb. 12, 2021. Their preliminary data, shared in a letter to Annals of the Rheumatic Diseases, showed that patients on rituximab and mycophenolate regimens were less likely to have an antibody response, while those on methotrexate and tumor necrosis factor (TNF) inhibitors had detectable antibodies.4

You Might Also Like
  • Researchers Explore Response to COVID-19 Vaccines in the Elderly
  • More Info on the J&J COVID-19 Vaccine Thrombosis Scare
  • How Immunosuppression May Affect COVID-19 Vaccine Response
Explore This Issue
August 2021
Also By This Author
  • Rheumatologists Can Now Treat Patients Via Telemedicine

In another preprint study of 133 patients with chronic inflammatory diseases on various immunosuppressive therapies, those on B cell-depletion regimens had a 36-fold reduction in vaccine antibody response, and patients on glucocorticoids had a 10-fold reduction. In this study, Dr. Kim and his colleagues found that patients treated with immunosuppressive therapies—jakinibs and antimetabolites, including methotrexate—exhibit impaired SARS-CoV-2 vaccine-induced immunity, with glucocorticoids and B cell depletion therapy more severely impeding optimal responses.5 Other targeted therapies, such as TNF, interleukin (IL) 12, IL-23 and integrin inhibitors, had only modest impacts on antibody formation and neutralization.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

According to the ACR guidance, to optimize vaccine response, rheumatologists may advise patients on the following therapies to hold their medications for a short time after their vaccines if they have stable disease:2

  • Mycophenolate: Hold for one week after each vaccine dose.
  • Methotrexate: Hold for one week after each mRNA vaccine dose and for two weeks after a single-dose vaccine.
  • Jakinibs: Hold for one week after each vaccine dose.
  • Abatacept SQ: Hold for one week prior to and one week after the first vaccine dose only.
  • Abatacept IV: Time the vaccine to occur four weeks after completed abatacept infusion and postpone next infusion for one week after the first vaccine dose.
  • Cyclophosphamide IV: Schedule infusion for one week after each vaccine dose if possible.
  • Rituximab: If a patient’s COVID-19 risk is low or they can mitigate risk with preventive measures, try to schedule each vaccine dose four weeks before the start of the next rituximab cycle, and then hold rituximab for two to four weeks after final vaccine dose if disease activity allows.
  • Acetaminophen and NSAIDs: Hold for 24 hours before vaccination.

“In my patients on mycophenolate, I suggest we hold their medication for one week after their vaccine. We believe that by holding such immunosuppressants, the response may be better,” says Dr. Paik.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Kim stresses to his hesitant patients that because COVID-19 is more severe and deadly in some immunosuppressed patients, and the safety of vaccination appears to be excellent for immunosuppressed patients, he strongly recommends vaccination for them.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions Tagged With: COVID-19, vaccination, vaccine, vaccine hesitancyIssue: August 2021

You Might Also Like:
  • Researchers Explore Response to COVID-19 Vaccines in the Elderly
  • More Info on the J&J COVID-19 Vaccine Thrombosis Scare
  • How Immunosuppression May Affect COVID-19 Vaccine Response
  • COVID-19 Vaccination Strategies Suggested for Patients on Anti-Rheumatic Immunosuppressive Therapy

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)